Skip to main content

Pediatric Biopharmaceutics – Part 1: “Drug Product Development” and “GI Luminal Water Volumes”

Thank you

This live web event has ended. Thank you for attending.


  • Robert L. Ternik, Ph.D., R.Ph., Eli Lilly and Company

    Dr. Ternik is Senior Research Advisor, Synthetic Molecule Design and Development at Eli Lilly and Company in Indianapolis, IN. He is responsible for creating and implementing patient centered design and drug delivery capability across Lilly’s synthetic molecule drug product portfolio. Dr. Ternik received his bachelor’s in Pharmacy from Butler University, Indianapolis, Indiana. After working as a hospital pharmacist for the USVA and as a Research Pharmacist for Merrell Dow, he attended to the University of Iowa and received his Ph.D. in Pharmaceutics. Upon completion of his graduate studies, Dr. Ternik worked for Janssen Pharmaceuticals before joining Eli Lilly in 1997. He has contributed to Lilly in both scientific and management roles in Product Research and Development, including 7 years as the Director of Formulation and Process Development. He has significant experience in formulation development and manufacturing process scale up and tech transfer. Dr. Ternik has led and overseen the development more than 40 pivotal clinical and commercial formulations. He has experience and expertise in oral, parenteral and alternative dosage form development, with a primary focus on oral products. In addition to his responsibilities in advancing Lilly’s synthetic molecule portfolio,

    Dr. Ternik is highly engaged in the IQ Consortium Drug Product Leadership Group (DPLG). He was a co-founder and chair of the IQ’s Pediatric Working Group under the DPLG and is a former chair of the DPLG. He sits on the Lilly Pediatric Steering Committee and is actively engaged in both US and European based pediatric product development consortia. Dr. Ternik is a pharmaceutical industry representative on the Federal Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) through HHS and the NICHD. He was also recently appointed to the Dean’s Advisory Council for the College of Pharmacy and Health Sciences at Butler University. He has expertise in and has published on product development for special patient populations, such as pediatrics and geriatrics. He is an active advocate for, and leader in, advancing Lilly’s capability in product design, with focus on addressing unmet patient needs through human-centered design.

  • Hannah Batchelor, Institute of Pharmacy and Biomedical Sciences

    Professor Hannah Batchelor is a pharmaceutical scientist who has worked in academia, the NHS and within pharmaceutical industry. She is currently based at the Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde in Glasgow.

    She works on the design and manipulation of medicines to create age appropriate drug formulations to maximise clinical efficacy in paediatric patients. Her research interests lie in the optimisation of drug formulations to maximise their biopharmaceutical performance and acceptability to children. Her research is informed by the views of children, young people and parents to ensure that the patients are at the centre of new developments.

    Hannah is recognised as an expert in biopharmaceutics and leads the Academy of Pharmaceutical Scientists Focus group on biopharmaceutics in the UK as well as the European Paediatric Formulation Initiative’s biopharmaceutics workstream. She is also an active member of the Understanding paediatric gastrointestinal processes (UNGAP) consortium. She has ongoing research projects that explore paediatric biopharmaceutics in conjunction with Janssen; Certara; the FDA and GlaxoSmithKline.

November 10, 2020
Tue 12:30 PM EST

Duration 1H 30M

This live web event has ended.